Climb Bio (CLYM) Current Assets (2020 - 2026)

Climb Bio has reported Current Assets for 7 years, with the latest figure at $113.4 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 13.09% year-over-year to $113.4 million; the trailing twelve-month figure through Mar 2026 stood at $113.4 million (up 13.09% YoY), and the FY2025 full-year result was $105.8 million, down 31.65% from the prior year.
• Current Assets for Q1 2026 stood at $113.4 million, up from $105.8 million in the prior quarter.
• The five-year high for Current Assets was $226.0 million in Q2 2024, with the low at $87.4 million in Q2 2025.
• Historically, Current Assets has averaged $128.0 million across 5 years, with a median of $114.2 million in 2023.
• Annual changes were most pronounced in 2024 — Current Assets soared 97.82% — and 2025, when it sank 61.33%.
• Climb Bio's Current Assets stood at $134.4 million in 2022, then declined by 17.96% to $110.3 million in 2023, then soared by 40.47% to $154.9 million in 2024, then tumbled by 31.65% to $105.8 million in 2025, then gained by 7.14% to $113.4 million in 2026.
• The last three Current Assets figures came in at $113.4 million (Q1 2026), $105.8 million (Q4 2025), and $91.0 million (Q3 2025), per Business Quant data.